ArticleEuropean journal of nuclear medicine and molecular imaging2026
Comparison of mCRPC [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and outcomes of [European journal of nuclear medicine and molecular imaging · 2026Article
- Outcomes of [European journal of nuclear medicine and molecular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSeveral clinical and preclinical studies showed that ARPI medication such as enzalutamide increases the expression of PSMA in mCRPC patients and may potentially act as a sensitizer for PSMA RLT. In this study we aim to provide insight into the efficacy and safety profile of concurrent treatment with [
methodsIn total n = 63 mCRPC patients received [
resultsPatients treated with PSMA RLT in combination with enzalutamide achieved a significantly higher response rate (61.9% vs. 43.5%) and experienced a significantly longer PFS (6.1 months vs. 3.5 months). Statistically significant difference in OS between the groups was not reached (p = 0.097). The adverse event profiles between the treatment groups did not differ for renal toxicity, hematoxicities and xerostomia but a more frequent rate of low-grade fatigue in the enzalutamide group was observed. The combination of PSMA RLT and enzalutamide was both safe and overall well tolerated.
conclusionThe results suggest that concurrent medication of enzalutamide during PSMA RLT may enhance response and clinical outcomes, underscoring the potential of this specific combination as a promising approach in mCRPC. Future studies, ideally in prospective setting with larger patient cohorts are warranted.
Indexed as
Identifiers
41309998What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.